Authors' conclusion: this clinical trial confirms previous findings on the safety and efficacy of oral propranolol treatment of infantile hemangiomas. Propranolol produces a significant decrease in volume, redness and elevation in all stages of the natural history of the tumour. These facts justify its use as a first choice drug in potentially disfiguring or complicated child hemangiomas.
Reviewers' commentary: the results of this study demonstrate that propranolol is effective in the treatment of infantile hemangiomas. However the optimal dose is unknown and larger trials are lacking to determine the incidence of any adverse effects. Since most of infantile hemangiomas produce only aesthetic consequences and the vast majority of them regress and disappear in the long term, currently the use of propranolol should be restricted to selected cases.